Peer-Reviewed Publication
Clin Cancer Res2026July 27, 2026Journal Article
The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer.
Natalie I Vokes1, Jessica L Symons2, Brooke Rhead3, Lingzhi Hong1, Pooja A Shah4, Zhongwu Lai5, Zhou Zhu6, Santiago Treviño7, Julian Bryan1, Jia Wu7, Jianjun Zhang1, Don Gibbons1, John V Heymach1, Ross Stewart8, Sonia Iyer5, Konstantinos Leventakos9, Stamatina Fragkogianni10, Calvin Chao11, Jordi A Rodon4
1The University of Texas MD Anderson Cancer Center Houston, TX United States.
2Tempus Labs (United States) United States.
3Tempus Labs (United States) Chicago, IL United States.
4The University of Texas MD Anderson Cancer Center Houston, Texas United States.
5AstraZeneca (United States) Waltham, MA United States.
6AstraZeneca (United States) United States.
7The University of Texas MD Anderson Cancer Center Houston United States.
8AstraZeneca (United Kingdom) Cambridge United Kingdom.
9Mayo Clinic Rochester United States.
10Tempus Labs (United States) NYC United States.
11Artera Menlo Park, CA United States.
Abstract
INTRODUCTION: Homozygous deletion of 9p21, containing CDKN2A/B and MTAP (CMdel), underlies emerging therapeutic strategies including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcomes of CMdel in NSCLC remain incompletely defined.
METHODS: We analyzed Tempus Lens records with paired DNA/RNA sequencing. After quality filtering, 16,947 patients were included in the primary da…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans